CG Oncology
CGON
226 hedge funds and large institutions have $6.66B invested in CG Oncology in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 37 closing their positions.
174% more call options, than puts
Call options by funds: $272M | Put options by funds: $99.2M
28% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 72
12% more capital invested
Capital invested by funds: $5.93B → $6.66B (+$730M)
1.92% more ownership
Funds ownership: 104.38% → 106.3% (+1.9%)
8% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 37
3% less funds holding
Funds holding: 233 → 226 (-7)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFCM
Seven Fleet Capital Management
Mountain View,
California
|
+$118M |
| 2 |
RI
RTW Investments
New York
|
+$100M |
| 3 |
BlackRock
New York
|
+$77.9M |
| 4 |
SG Americas Securities
New York
|
+$55.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$51.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$67.7M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$66.7M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$44.1M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$43.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$30.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RAM
251
RWC Asset Management
London,
United Kingdom
| – | -$223K | -3,295 | Closed |
|
|
BC
252
Bayforest Capital
London,
United Kingdom
| – | -$210K | -3,104 | Closed |
|
253
Jane Street
New York
| – | -$202K | -3,097 | Closed |
|
|
MF
254
Magnetar Financial
Evanston,
Illinois
| – | -$208K | -3,076 | Closed |
|
|
ADEF
255
ABS Direct Equity Fund
Stamford,
Connecticut
| – | -$176K | -2,600 | Closed |
|
256
Group One Trading
Chicago,
Illinois
| – | -$93.8K | -1,435 | Closed |
|
|
EB
257
Eastern Bank
Boston,
Massachusetts
| – | -$6.9K | -102 | Closed |
|
|
MCM
258
MAI Capital Management
Independence,
Ohio
| – | -$1.83K | -27 | Closed |
|
|
MPWT
259
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | -$1.62K | -24 | Closed |
|
|
PA
260
Parallel Advisors
San Francisco,
California
| – | -$744 | -11 | Closed |
|
|
ASN
261
Advisory Services Network
Atlanta,
Georgia
| – | -$338 | -5 | Closed |
|
|
RFP
262
Root Financial Partners
Encinitas,
California
| – | -$135 | -2 | Closed |
|
|
TPWA
263
Twin Peaks Wealth Advisors
Burlingame,
California
| – | -$135 | -2 | Closed |
|
CGON Hedge Fund Activity: Q2 2026 in Review
226 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q2 2026, worth a combined $6.66B — up 12% from $5.93B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CGON and 34 opened new positions — a net loss of 3 holders — while 72 trimmed existing stakes and 92 added.
The largest buyer was Seven Fleet Capital Management, adding an estimated $118M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $67.7M sold.
- 226 institutional investors held CG Oncology (CGON) as of Q2 2026, down from 233 in Q1 2026.
- Funds reported $6.66B of CG Oncology stock for Q2 2026, up 12% quarter-over-quarter.
- 34 funds opened new CG Oncology positions in Q2 2026 and 37 closed out, a net change of -3 holders.
- The largest CG Oncology buyer in Q2 2026 was Seven Fleet Capital Management, an estimated $118M added.
- The largest CG Oncology seller in Q2 2026 was Driehaus Capital Management, an estimated $67.7M sold.
Based on aggregated 13F filings for Q2 2026.